Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna, Inc. (MRNA) reported trailing twelve months (TTM) revenue of $1.94B as of December 2025, which represents a 39.9% decrease year-over-year. The company's operating margin has expanded to -126.4% from -129.0% a year ago. In terms of profitability, MRNA reported a net loss of $2.82B. Valuation-wise, the stock trades at a Price-to-Sales (P/S) ratio of 6.1x. The company generated $757.00M in free cash flow over the last twelve months, indicating its ability to reinvest in growth or return capital to shareholders. Data based on the most recent quarterly reports.
Quarterly standardized metrics.
Stock price and market valuation
Top-line sales performance
EBITDA and Net Income trends
Price-to-earnings and price-to-sales ratios
Free cash flow generation
Operating and net margin percentages
